Patients in the US undergo first doses of GE HealthCare’s new PET radiotracer, Flyrcado (flurpiridaz F 18) injection
Patients undergo first doses of GE HealthCare's PET radiotracer Flyrcado (flurpiridaz F 18) injection at early adopter sites ...
Hosted on MSN2d
GE HealthCare delivers first PET MPI agent doses for CAD detection
GE HealthCare has delivered the initial subject doses of a positron emission tomography (PET) myocardial perfusion imaging ...
GE HealthCare announces first patient doses of Flyrcado for CAD detection
GE HealthCare (GEHC) has delivered the first patient doses of Flyrcado or flurpiridaz F 18 njection, a first-of-its-kind unit dose positron ...
Hosted on MSN14d
GE HealthCare projects $4.61-$4.75 adjusted EPS for 2025 amid margin expansion and Flyrcado launch
The company announced the planned launch of Flyrcado, a radiopharmaceutical product for myocardial perfusion imaging, in April 2025. It is expected to generate $30 million in revenue for 2025 and ...
Investing23d
GE HealthCare Technologies Inc (GEHC)
ARLINGTON HEIGHTS, Ill. - GE HealthCare (NASDAQ: NASDAQ:GEHC) has received U.S. Food and Drug Administration (FDA) approval for Flyrcado™ (flurpiridaz F 18) injection, a new... ByInvesting.com ...